About the Company
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GERN News
Can Geron Corporation maintain momentum following FDA’s backing?
Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering ...
Geron Stock Is Soaring After Hours: What's Going On?
Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food ...
Geron surges after FDA AdCom backing for lead drug
Shares of Geron Corporation (NASDAQ:GERN) surged ~85% in the morning hours on Friday, marking the biggest intraday gain in ...
What's Going On With Cancer Focused-Geron Stock On Friday?
Geron Corporation’s (NASDAQ:GERN) shares are trading lower with a high session volume of 5.82 million compared to the average ...
Geron's blood disorder drug gets FDA advisers' backing
Advisers to the U.S. Food and Drug Administration on Thursday backed benefits of Geron's blood disorder drug, saying it ...
Cancer drug from Peninsula company wins FDA advisory committee thumbs up
An advisory committee has just greenlighted a Bay Area company's drug for blood cancer patients. Here's the latest.
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment
The FDA's review of Geron Corporation's imetelstat application for anemia in lower-risk MDS patients. Expert analysis ...
Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in ...
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer
Despite skepticism from FDA reviewers, the Oncologic Drugs Advisory Committee on Thursday strongly supported Geron’s ...
Geron wins FDA AdCom backing for blood cancer drug
The FDA's expert advisors have voted in favor of Geron's (GERN) blood cancer therapy imetelstat, potentially paving the way ...
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is ...
Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?
Wall Street continues to maintain a risk-off sentiment in Friday’s session, echoing the pessimism triggered by Thursday’s ...
Loading the latest forecasts...